

Alkermes plc.
Form 8-K
December 11, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 6, 2017

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

Ireland (State or other jurisdiction of incorporation)	001-35299 (Commission File Number)	98-1007018 (IRS Employer Identification No.)
--------------------------------------------------------------	------------------------------------------	----------------------------------------------------

Connaught House, 1 Burlington Road Dublin 4, Ireland (Address of principal executive offices)	(Zip Code)
-----------------------------------------------------------------------------------------------------------	------------

(Registrant's telephone number, including area code): + 353-1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: Alkermes plc. - Form 8-K

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Effective February 1, 2018, Elliot W. Ehrich, M.D., Executive Vice President, Research and Development of Alkermes, Inc., a U.S. subsidiary of Alkermes plc (the “Company”), will transition from his current role and become Executive Vice President, Science and Therapeutics of Alkermes, Inc. In his new role, he will provide strategic direction for the Company’s development and marketed product portfolios, and engage with the scientific and clinical communities around these products. Dr. Ehrich and the Company agreed upon this transition on December 6, 2017.

Item 7.01 Regulation FD Disclosure.

Craig Hopkinson, M.D. and Mark Namchuk, Ph.D. will assume all leadership responsibilities for the Company’s research and development organization, effective February 1, 2018. Dr. Hopkinson will serve as Senior Vice President, Medicines Development and Medical Affairs, and Chief Medical Officer; Dr. Namchuk will serve as Senior Vice President, Research, Pharmaceutical and Non-Clinical Development.

The information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALKERMES PLC

Date: December 11, 2017 By: /s/ David
J. Gaffin
David J.
Gaffin
Senior
Vice
President,
Chief
Legal
Officer